Global and USA Cancer Immunotherapy Market 2017-2022: This Space - Tucson News Now

Global and USA Cancer Immunotherapy Market 2017-2022: This Space will be a Significant Revenue Generator (Excess of $80 Billion) for the Biopharmaceutical Industry by 2020

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact

SOURCE Research and Markets

DUBLIN, March 7, 2018 /PRNewswire/ --

The "Global Cancer Immunotherapy Market Analysis & Forecast to 2022" report has been added to's offering.

Research and Markets Logo

"Global & USA Cancer Immunotherapy Market Analysis to 2020

reveals that the cancer immunotherapy space will be a significant revenue generator (excess of $80 billion) for the biopharmaceutical industry by 2020. The market has been supported by the approval of Bristol-Myers' Yervoy drug for melanoma, BMS's Opdivo and Merck's Keytruda.

Within the cancer therapeutics space, which today is worth over $100 billion globally, immunotherapeutic drugs have gained worldwide acceptance. This is because they are targeted therapeutics that have high specificity for cancer cells. Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $54 billion in 2016 alone and are forecast to surpass $100 billion in 2022.

Over the next decade, immunotherapies will be the backbone of cancer treatments in 60% of cancer types. It is forecast that by 2020, Avastin, Nivolumab, Revlimid, Rituxan and Xtandi will be the top five cancer drugs. A single drug, Bristol-Myers Squibb's Yervoy, for example has earned revenues of about $960 million in 2013 and it is expected to have a market value of $1,775.2 million in 2020. Industry Experts have predicted that Keytruda and Opdivo will generate sales revenues of $2.9 billion and $4.3 billion respectively in 2019.

The CAR-T industry is addressing unmet needs in specific relapsed cancers, however does early clinical trial data support a blockbuster status for this upcoming therapy? Some patients do indeed show long term activity and high remission rates, but there is a large proportion of patients with toxicities such as cytokine release syndrome and neurotoxicity. The main players within the CAR-T market are Juno Therapeutics, Kite Pharma, Novartis and Cellectis. The market is moving ahead, backed by years of R&D, from both academia and industry, investors capitol and small clinical studies.

The interest on ADCs can be seen with the recent approvals of Adcetris (brentuximab vedotin) and Kadcyla (ado-trastuzumab emtansine). Currently, More than 15 companies are developing 30 different ADCs targeting both hematologic malignancies and solid tumors. ADCs represent a novel class of therapeutic agents, gaining increasing attention from both large and small pharmaceutical companies.

As the ADCs carry a chemotherapy drug, they are believed to be more efficient and effective in the treatment of a disease. Due to shrinking pipelines and increasing pressure from patent expirations, big pharmaco' recognized the vaccine market as a potential resource for investors. Cancer vaccines have been found to earn a higher profit than the generic drugs, owing to the nature of the disease and the urgency in the demand for these vaccines. The global market for cancer vaccines was worth about $4.4 billion and it is likely to reach $8.4 billion in 2020.

Immunotherapy is a proven powerful tool, either as a monotherapy or as a combination therapy with chemotherapy or radiation. For patients with metastatic skin cancer or kidney cancer, immunotherapy has been found to be more effective than the conventional options, with the possibility of even a complete cure. Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $41.0 billion in 2014 alone.

Key Questions Answered in this Report

  • What is the global market for cancer immunotherapeutics by product class such as MAbs, vaccines and non-specific immunotherapies, through 2022?
  • What is the global market for cancer immunotherapeutics by geography, through 2022?
  • What is the global market for cancer immunotherapeutics by indication, through 2022?
  • What is the global market for MAbs by type such as naked MAbs and ADCs, through 2022?
  • What are the market values for Herceptin, Avastin, Erbitux, Yervoy, Mabthera, Adectris, and Keytruda?
  • What is the global market for cancer vaccines?
  • What is the global market for cytokines in cancer immunotherapy?
  • The projected market values for Nivolumab, Tecentriq, DCVax-L, Imfinzi?
  • What immunotherapies were approved between 1986 and 2017?
  • What monoclonal antibodies (MAbs) were approved by the FDA to treat different types of cancers?
  • What are naked MAbs and how many of them have been approved by the FDA?
  • What are antibody-drug conjugates (ADCs) and how many of them are available in the market?
  • What are the common cytotoxic wareheads used in ADCs?
  • What are the important clinical assets in ADCs?
  • How many bispecific MAbs are in late-stage development?
  • What are the common side effects of MAbs in cancer immunotherapy?
  • What are cancer vaccines and how many of them have been licensed to be marketed?
  • How many cytokines have been approved for being used in cancer immunotherapy?
  • What are the major checkpoint inhibitors in clinical development?
  • What is the current status of anti-PD-1 drugs, dentritic cell therapies, T-cell therapies and cancer vaccines?
  • What are the most valuable R&D projects in cancer immunotherapy and what would be their approximate sales revenues in 2022?
  • Number of melanoma drugs approved between 1998 and 2017?
  • Number of lung cancer drugs approved between 1998 and 2017?
  • Number of brain cancer drugs approved between 1998 and 2017?
  • What is CAR T Therapy?
  • What are the main challenges associated with CAR T therapy?
  • What is the status of CAR T therapeutic approval?
  • What are the current regulations for immunotherapies in USA, Europe & Japan?
  • What are the main manufacturing steps in CAR T therapy?
  • What challenges lie ahead for CAR T production?

Key Topics Covered:
1.0 Executive Summary
1.1 Objectives of Report
1.2 Key Questions Answered in this Report
1.3 Data Sources and Methodology

2.0 Cancer Immunotherapy: An Overview
2.1 Human Immune System
2.2 Types of Cancer Immunotherapy
2.3 Monoclonal Antibodies (Mabs) to Treat Cancer
2.4 Types of Monoclonal Antibodies (MAbs)
2.5 Cancer Vaccines
2.6 Non-Specific Cancer Immunotherapies and Adjuvants
2.7 New Frontiers in Cancer Immunotherapy Research
2.8 Cancer Immunotherapy: Timeline of Progress

3.0 Current Status of Cancer Immunotherapy: An Overview
3.1 Programmed Death (PD-1) Inhibitors
3.2 Keytruda (Pembrolizumab, MK-3475)
3.3 Tecentriq from Roche
3.4 Pidilizumab from CureTech
3.5 An Overview of Anti-PD-1 Clinical Development
3.6 Studies with Yervoy (Ipilimumab)
3.7 Studies with Tremelimumab
3.8 KAHR-102
3.9 TIM3 Antibody
3.10 BMS-989016
3.11 ImmuTune IMP701 and ImmuFact IMP321
3.12 Dendritic Cell Therapies
3.13 Chimeric Antigen Receptor T-Cells (CAR-T) Therapies
3.14 Cancer Vaccines
3.15 Miscellaneous Immunotherapies
3.16 Most Valuable R&D Projects in Cancer Immunotherapy

4.0 Challenges in Cancer Medicine Research: An Overview
4.1 Years of Failures and Emerging Successes in Melanoma Medicine Research
4.2 A New Era for Lung Cancer Medicines
4.3 Ray of Hope for Brain Cancer Patients

5.0 Cancer Immunotherapeutic Products: An Overview
5.1 I-Labelled Tositumomab (Bexxar)
5.2 Y-Labelled Ibritumomab (Zevalin)
5.3 Alemtuzumab (Campath)
5.4 Adotrastuzumab Emtansine (Kadcyla)
5.5 Bacillus Calmette-Guerin (BCG)
5.6 Bevacizumab (Avastin)
5.7 Brentuximab Vedotin (Adcetris)
5.8 Cetuximab (Erbitux)
5.9 Cervarix
5.10 Denileukin Diftitox (Ontak)
5.11 Gardasil
5.12 Gemtuzumab (Mylotarg)
5.13 Hepatitis B Vaccine
5.14 Interferon Alfa (IFN-alfa)
5.15 Interleukin-2 (IL-2)
5.16 Ipilimumab (Yervoy)
5.17 Ofatumumab (Arzerra)
5.18 Panitumumab (Vectibix)
5.19 Pembrolizumab (Keytruda)
5.20 Rituximab (Mabthera)
5.21 Sargramostim (Leukine)
5.22 Sipuleucel-T (Provenge)
5.23 Trastuzumab (Herceptin)

6.0 Available Immunotherapies for Cancer by Disease Type: An Overview
6.1 Melanoma Skin Cancer and Immunotherapy
6.2 Breast Cancer and Immunotherapy
6.3 Immunotherapy for Prostate Cancer
6.4 Immunotherapy for Lung Cancer
6.5 Immunotherapy for Colorectal Cancer
6.6 Immunotherapies in Development for Lymphoma
6.7 Immunotherapy for Kidney Cancer
6.8 Dominance of MAbs and Vaccines in Cancer Clinical Research
6.9 Oncology Biologics Losing Patent Protection

7.0 Cancer Incidence and Mortality: An Overview
7.1 Global Economic Burden of Cancer
7.2 Global Burden of Cancer
7.3 Top Five Most Frequent Cancers, Globally
7.4 Cancer Deaths in Women
7.5 Prevalence and Mortality for Cancer Types Addressed by Immunotherapy

8.0 Market Analysis
8.1 Global Oncology Market
8.2 Top Ten Companies in Oncology Drug Sales
8.3 Top Five Oncology Drugs
8.4 Global Oncology Therapeutics Market by Cancer Type

9.0 Market for Cancer Immunotherapy
9.1 Key Drivers
9.2 Global Market for Cancer Immunotherapeutics
9.3 Global Market for Cancer Immunotherapy by Product Class
9.4 Global Market for Immunotherapy Drugs by Cancer Type
9.5 Global Market for Monoclonal Antibodies for Cancer by Type
9.6 Global Market for Cancer Vaccines
9.7 Global Market for Non-Specific Cancer Immunotherapeutics
9.8 Market Values for Selected Forthcoming Cancer Immunotherapeutics

10.0 Company Profiles
10.1 Ablynx NV
10.2 Activartis Biotech GmbH
10.3 Advaxis Inc
10.4 Aduro BioTech Inc
10.5 Agenus Inc
10.6 AlphaVax Inc
10.7 A. Menarini Industrie Farmaceutiche Riunite Srl
10.8 Amgen Inc
10.9 Antigen Express Inc
10.10 Argos Therapeutics Inc
10.11 Bavarian Nordic A/S
10.12 Bellicum Pharmaceuticals Inc
10.13 Biogen Idec Inc
10.14 Biovest International Inc
10.15 Bristol-Myers Squibb Company
10.16 Cellectis
10.17 Cellerant Therapeutics Inc
10.18 Celldex Therapeutics
10.19 CEL-SCI Corp.
10.20 CureTech Ltd.
10.21 Delta-Vir GmbH
10.22 Dendreon Corp.
10.23 DenDrit Biotech USA
10.24 DNAtrix Inc
10.25 Eli Lilly and Co.
10.26 EMD Serono Inc
10.27 Etubics Corp.
10.28 Galena Biopharma Inc
10.29 Genentech Inc
10.30 Genmab AS
10.31 GlaxoSmithKline
10.32 Gliknik Inc
10.33 GlobeImmune Inc
10.34 Heat Biologics Inc
10.35 Immatics Biotechnologies GmbH
10.36 ImmunoCellular Therapeutics Ltd.
10.37 Immunocore Ltd.
10.38 ImmunoFrontier Inc
10.39 ImmunoGen Inc
10.40 Immunomedics Inc
10.41 Immunotope Inc
10.42 Immunovaccine Inc
10.43 Inovio Pharmaceuticals Inc
10.44 Janssen Biotech Inc
10.45 Juno Therapeutics Inc
10.46 Kite Pharma Inc
10.47 MabVax Therapeutics Holdings Inc
10.48 MedImmune LLC
10.49 Merck & Co., Inc
10.50 Merrimack Pharmaceuticals Inc
10.51 Morphotek Inc
10.52 NewLink Genetics Corp.
10.53 Northwest Biotherapeutics Inc
10.54 NovaRx Corp.
10.55 OncoPep Inc
10.56 Oncothyreon Inc
10.57 OSE Pharma SA
10.58 Oxford BioTherapeutics Ltd.
10.59 Pique Therapeutics
10.60 Polynoma LLC
10.61 Prima BioMed Ltd.
10.62 Progenics Pharmaceuticals Inc
10.63 Regen Biopharma Inc
10.64 Roche Holdings Inc
10.65 Seattle Genetics Inc
10.66 Sorrento Therapeutics Inc
10.67 Spectrum Pharmaceuticals Inc
10.68 Synthon Pharmaceuticals Inc
10.69 TapImmune Inc
10.70 ThioLogics Ltd.
10.71 Transgene SA
10.72 TVAX Biomedical Inc
10.73 Vaccinogen Inc
10.74 Viventia Biotechnologies Inc
10.75 Wilex AG
10.76 Ziopharm Oncology Inc

11.0 Cancer Immunotherapy Market Participants by Product Segment

12.0 CAR T Therapy
12.1 Challenges Relating to Chimeric Antigen Receptor T Cells in Immunotherapy

13.0 Regulations Pertaining to Immunotherapy Regulation in the USA
13.1 Center for Biologics Evaluation and Research (CBER)

14.0 Regulations for Immunotherapy in Japan
14.1 PMDA and Immunotherapy

15.0 European Regulation and Immunotherapeutics
15.1 Introduction
15.2 Challenges for Immunotherapy in EMEA
15.3 Challenges Relating to Biomarkers in Immunotherapy
15.4 Challenges Relating to Chimeric Antigen Receptor T Cells in Immunotherapy
15.5 Estimating Optimal Cut-Off Parameters
15.6 EU-Approved Immunotherapies in Melanoma
15.7 Key Contacts Within EMA for Immunotherapeutics

16.0 Manufacturing of Immunotherapies
16.1 Introduction
16.2 Generation of CAR-Modified T Cells
16.3 Manufacturing Devices and Instruments Required for Immunotherapy Production
16.4 Good Manufacturing Procedure (GMP) for Immunotherapy
16.5 Case Study Production of Lentivirus Induced Dendritic Cells under GMP Conditions
16.6 Quality Control
16.7 Regulatory Affairs
16.8 Key Challenges in Manufacturing

17.0 Supply Chain & Logistics
17.1 Introduction
17.2 Case Study: Juno Therapeutics

18.0 Pricing & Cost Analysis
18.1 Introduction
18.2 CAR T Therapy Market Evaluation

19.0 Current Deals Within the CAR T Market

20.0 CAR T Therapy Company Case Studies
20.1 Juno Therapeutics
20.2 Kite Pharma
20.3 Cellectis

A1 Highlights and Approvals in 2017
A2 Highlights and Approvals in 2016

For more information about this report visit

Media Contact:

Laura Wood, Senior Manager  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:

©2017 PR Newswire. All Rights Reserved.

Powered by Frankly